Skip to main content
Log in

Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Sustained-release bupropion (bupropion SR) is a unique, non-nicotine smoking cessation aid that is hypothesised to act upon neurological pathways involved in nicotine dependence. Pharmacokinetic and metabolism studies reveal that bupropion SR is metabolised by multiple pathways with no single pathway predominating. When one pathway is inhibited, others are available to compensate. Therefore, only a few clinically relevant drug-drug interactions involving bupropion SR have been observed, although the potential for interactions exists, as with any extensively metabolised drug. Population pharmacokinetic/pharmacodynamic analyses of data from patients receiving daily oral doses of 100mg, 150mg, or 300mg reveal that the anti-smoking efficacy of bupropion SR is directly related to dose. The incidences of dry mouth and insomnia were directly related to bupropion plasma concentrations while the incidence of anxiety was inversely proportional to bupropion plasma concentrations. To maximise efficacy (with an acceptable safety profile), the optimal daily dose for the majority of patients is 300mg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2

Similar content being viewed by others

Notes

  1. Tradenames are used for identification purposes only and do not imply endorsement.

References

  1. Ulmer H, Diem G, Bischof HP, et al. Recent trends and sociodemographic distribution of cardiovascular risk factors: results from two population surveys in the Austrian WHO CINDI demonstration area. Wien Klin Wochenschr 2001; 113: 573–9

    PubMed  CAS  Google Scholar 

  2. Breslau N, Johnson EO, Hiripi E, et al. Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Arch Gen Psychiatry 2001; 58: 810–6

    Article  PubMed  CAS  Google Scholar 

  3. Molarius A, Parsons RW, Dobson AJ, et al. Trends in cigarette smoking in 36 populations from the early 1980s to the mid-1990s: findings from the WHO MONICA project. Am J Public Health 2001; 91: 206–12

    Article  PubMed  CAS  Google Scholar 

  4. Anonymous. Cigarette smoking among adults: United States, 1999. Morb Mortal Wkly Rep 2001; 50: 869–73

  5. Prignot J. Towards a tobacco-free world. Monaldi Arch Chest Dis 2001; 56: 79–83

    PubMed  CAS  Google Scholar 

  6. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: quick reference guide for clinicians. Rockville (MD): US Department of Health and Human Services. Public Health Service, 2000 Oct

  7. Balfour DJK. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract 2001; 55: 53–7

    PubMed  CAS  Google Scholar 

  8. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401

    PubMed  CAS  Google Scholar 

  9. Balfour DJ, Wright AE, Benwell ME, et al. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 2000; 113: 73–83

    Article  PubMed  CAS  Google Scholar 

  10. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000; 393: 295–314

    Article  PubMed  Google Scholar 

  11. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. Bupropion elicits significant activity at the dopamine transporter in humans: a positron emission tomography study. Poster presented at the 40th annual meeting of the American College of Neuropsychopharmacology; 2001 Dec 12, Waikoloa (Hawaii)

  12. Delfs JM, Zhu Y, Druhan JP, et al. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 2000; 403: 430–4

    Article  PubMed  CAS  Google Scholar 

  13. Miller NS, Gold MS. A hypothesis for a common neurochemical basis for alcohol and drug disorders. Psychiatr Clin North Am 1993; 16: 105–17

    PubMed  CAS  Google Scholar 

  14. Dossin O, Hanoun N, Zajac JM. Involvement of locus coeruleus projections in opiate withdrawal but not in opiate tolerance in mice. Eur J Pharmacol 1996; 25: 271–4

    Article  Google Scholar 

  15. Golden RN, Rudorfer MV, Sherer MA, et al. Bupropion in depression: I. biochemical effects and clinical response. Arch Gen Psychiatry 1988; 45: 139–43

    Article  PubMed  CAS  Google Scholar 

  16. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88–92

    PubMed  CAS  Google Scholar 

  17. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321–7

    PubMed  CAS  Google Scholar 

  18. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91

    Article  PubMed  CAS  Google Scholar 

  19. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000; 59: 1007–24

    Article  PubMed  CAS  Google Scholar 

  20. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–5

    Article  PubMed  CAS  Google Scholar 

  21. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 227: 1195–202

    Article  Google Scholar 

  22. Shiffman S, Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 2000; 148: 33–40

    Article  PubMed  CAS  Google Scholar 

  23. Jamerson BD, Nides M, Jorenby DE, et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther 2001; 23: 744–52

    Article  PubMed  CAS  Google Scholar 

  24. Tonstad S, Murphy M, Astbury C, et al. Effectiveness and tolerability of Zyban in smokers with cardiovascular disease — week 26 follow-up phase results [oral presentation]. European Society of Cardiology; 2001 Sep 1–5; Stockholm: abstract no. 1460

  25. Dale LC, Glover ED, Sachs DPL, et al. Bupropion for smoking cessation: predictors of successful outcome. Chest 2001; 119: 1357–64

    Article  PubMed  CAS  Google Scholar 

  26. Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation. Nicotine Tob Res 2001; 3: 131–40

    Article  PubMed  CAS  Google Scholar 

  27. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001; 135: 423–33

    PubMed  CAS  Google Scholar 

  28. Zyban® (bupropion hydrochloride) sustained-release tablets: product information. UK: GlaxoSmithKline, 2001

  29. Anonymous. Bupropion to aid smoking cessation. Drug Ther Bull 2000; 38: 73–5

  30. Findlay JWA, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981; 21: 127–35

    Article  PubMed  CAS  Google Scholar 

  31. Goodale E, Ascher J, Batey S. Cytochrome P450 metabolism of bupropion [abstract]. J Am Geriatr Soc 1999; 49: S88

    Google Scholar 

  32. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737–43

    PubMed  CAS  Google Scholar 

  33. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001; 41: 770–8

    Article  PubMed  CAS  Google Scholar 

  34. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995; 35: 876–84

    PubMed  CAS  Google Scholar 

  35. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995; 29: 1139–48

    PubMed  CAS  Google Scholar 

  36. DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990; 10: 328–32

    Google Scholar 

  37. Hesse LM, Venkatakrishnan K, Court MG, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28(10): 1176–83

    PubMed  CAS  Google Scholar 

  38. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995; 15: 327–33

    Article  PubMed  CAS  Google Scholar 

  39. Kustra R, Corrigan B, Dunn J, et al. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol 1999; 39: 1184–8

    PubMed  CAS  Google Scholar 

  40. Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000; 20: 1448–53

    Article  PubMed  CAS  Google Scholar 

  41. Posner J, Bye A, Jeal S, et al. Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol 1984; 26: 627–30

    Article  PubMed  CAS  Google Scholar 

  42. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology 1984; 34: 1092–4

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

At the time this article was written, the author was employed by GlaxoSmithKline.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Andrew Johnston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnston, J.A., Ascher, J., Leadbetter, R. et al. Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation. Drugs 62 (Suppl 2), 11–24 (2002). https://doi.org/10.2165/00003495-200262002-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262002-00002

Keywords

Navigation